Publicaciones en las que colabora con XERARDO XUSTO GARCIA MERA (24)

2024

  1. Exploring Biginelli-based scaffolds as A2B adenosine receptor antagonists: Unveiling novel structure-activity relationship trends, lead compounds, and potent colorectal anticancer agents

    Biomedicine and Pharmacotherapy, Vol. 173

2023

  1. Exploring the Effect of Halogenation in a Series of Potent and Selective A2BAdenosine Receptor Antagonists

    Journal of Medicinal Chemistry, Vol. 66, Núm. 1, pp. 890-912

  2. Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs

    Biomedicine and Pharmacotherapy, Vol. 164

2022

  1. A 2B adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models

    Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 5

  2. Exploring Non-orthosteric Interactions with a Series of Potent and Selective A3Antagonists

    ACS Medicinal Chemistry Letters, Vol. 13, Núm. 2, pp. 243-249

  3. Optimization of 2-Amino-4,6-diarylpyrimidine-5-carbonitriles as Potent and Selective A1Antagonists

    Journal of Medicinal Chemistry, Vol. 65, Núm. 3, pp. 2091-2106

2021

  1. 3,4-Dihydropyrimidin-2(1H)-ones as Antagonists of the Human A2B Adenosine Receptor: Optimization, Structure-Activity Relationship Studies, and Enantiospecific Recognition

    Journal of medicinal chemistry, Vol. 64, Núm. 1, pp. 458-480

  2. Catalytic performance of a metal-free graphene oxide-Al2O3 composite assembled by 3D printing

    Journal of the European Ceramic Society, Vol. 41, Núm. 2, pp. 1399-1406

  3. Potent and Subtype-Selective Dopamine D2Receptor Biased Partial Agonists Discovered via an Ugi-Based Approach

    Journal of Medicinal Chemistry, Vol. 64, Núm. 12, pp. 8710-8726

2020

  1. Nitrogen-Walk Approach to Explore Bioisosteric Replacements in a Series of Potent A2B Adenosine Receptor Antagonists

    Journal of medicinal chemistry, Vol. 63, Núm. 14, pp. 7721-7739

  2. X-Ray Crystallography and Free Energy Calculations Reveal the Binding Mechanism of A2A Adenosine Receptor Antagonists

    Angewandte Chemie - International Edition, Vol. 59, Núm. 38, pp. 16536-16543

2019

  1. Trifluorinated Pyrimidine-Based A2B Antagonists: Optimization and Evidence of Stereospecific Recognition

    Journal of Medicinal Chemistry, Vol. 62, Núm. 20, pp. 9315-9330

2017

  1. Development of Fluorescent Probes that Target Serotonin 5-HT2B Receptors

    Scientific Reports, Vol. 7, Núm. 1

  2. Enantiospecific Recognition at the A2B Adenosine Receptor by Alkyl 2-Cyanoimino-4-substituted-6-methyl-1,2,3,4-tetrahydropyrimidine-5-carboxylates

    Journal of Medicinal Chemistry, Vol. 60, Núm. 8, pp. 3372-3382

  3. Multicomponent Assembly of the Kinesin Spindle Protein Inhibitor CPUYJ039 and Analogues as Antimitotic Agents

    ACS Combinatorial Science, Vol. 19, Núm. 3, pp. 153-160

2016

  1. Discovery of Potent and Highly Selective A2B Adenosine Receptor Antagonist Chemotypes

    Journal of Medicinal Chemistry, Vol. 59, Núm. 5, pp. 1967-1983

2014

  1. Structure-based design of new KSP-Eg5 inhibitors assisted by a targeted multicomponent reaction

    ChemBioChem, Vol. 15, Núm. 10, pp. 1471-1480

  2. Ugi-based approaches to quinoxaline libraries

    ACS Combinatorial Science, Vol. 16, Núm. 8, pp. 403-411

2013

  1. Discovery of 3,4-dihydropyrimidin-2(1 H)-ones as a novel class of potent and selective A2B adenosine receptor antagonists

    ACS Medicinal Chemistry Letters, Vol. 4, Núm. 11, pp. 1031-1036

  2. Selective and potent adenosine A3 receptor antagonists by methoxyaryl substitution on the N-(2,6-diarylpyrimidin-4-yl)acetamide scaffold

    European Journal of Medicinal Chemistry, Vol. 59, pp. 235-242